Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2025, v. 18, p. 703, doi. 10.2147/DMSO.S509866
- By:
- Publication type:
- Article